comparemela.com

Latest Breaking News On - Discovery center gmb - Page 1 : comparemela.com

Six biotech spinouts you should watch out for this year

Here are six biotech spinouts across the globe that have received funding over the past year, that you should know about.

Massachusetts institute of technologyUnited statesUnited kingdomTufts universityStanford universityKarolinska institutetArctic oceanUniversity of oxfordUniversity of manchesterUniversity of californiaMovers labUniversity of cambridgeArctic university of norway uiHm group venturesDiscovery center gmbNorwegian research council

Nodus Oncology Raises £2 4M in Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomCity ofKian waddellBasilea pharmaceuticaBert kleblDiscovery center gmbTechnology transfer fundNodus oncologyUnited kingdom basedManaging directorLead discovery center gmbh

Molecules could target cardio-metabolic diseases

Molecules could target cardio-metabolic diseases
leeds.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leeds.ac.uk Daily Mail and Mail on Sunday newspapers.

Baden wübergDaiichi sankyoKlaus dinkelRichard fosterRobin bonDiscovery centreResearch at leedsSchool of medicineDiscovery center gmbTech transfer office at university of leedsBoehringer ingelheimMerck kgaKhani gmbh coMerck kgaaUniversity of leedsKhan technology transfer fund

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea announces sale of preclinical oncology program to Nodus Oncology

Investegate announcements from Basilea Pharmaceutica AG, Basilea announces sale of preclinical oncology program to Nodus Oncology

Basel stadtBasel allschwilNils schrKian waddellDaiichi sankyoAdesh kaulDiscovery center gmbHead of corporate communications investor relationsBoehringer ingelheimBasilea pharmaceutica ltdSwiss exchangeMerck kgaBasilea pharmaceutica international ltdKhani gmbh coMerck kgaaMax planck society

Basilea announces sale of preclinical oncology program to

Sale of Basilea’s novel PARG inhibitor discovery programUpfront and milestone payments of up to CHF 242 million and approximately 5% participation in net.

Basel stadtBasel allschwilNils schrKian waddellDaiichi sankyoAdesh kaulDiscovery center gmbHead of corporate communications investor relationsBoehringer ingelheimBasilea pharmaceutica ltdSwiss exchangeMerck kgaBasilea pharmaceutica international ltdKhani gmbh coMerck kgaaMax planck society

vimarsana © 2020. All Rights Reserved.